Tofogliflozin Most Effective With High Baseline Insulin
These patients have largest improvements in fasting plasma glucose level, insulin secretion index
TUESDAY, Oct. 24, 2017 (HealthDay News) -- The sodium glucose co-transporter 2 inhibitor tofogliflozin is effective for reducing fasting plasma glucose and body weight, particularly in patients with a high insulin level at baseline, according to a study published online Oct. 15 in the Journal of Diabetes Investigation.
Kazuyuki Tobe, M.D., Ph.D., from the University of Toyama in Japan, and colleagues conducted a sub-analysis of a multicenter, open-label, 52-week, randomized controlled trial of tofogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus. Patients were categorized into tertiles by baseline insulin level: low (L) insulin (≤5.6 µU/mL), medium (M) insulin (5.6 to 10µU/mL), and high (H) insulin (>10µU/mL).
The researchers found that HbA1c, fasting plasma glucose levels, and body weight were significantly reduced from the baseline in all three groups. The changes in levels of plasma glucose AUC0-2 hours, C-peptide index AUC0-2 hours during the meal tolerance tests, and the insulin secretion index were the largest in the H group. The three groups were similar in terms of incidence of drug-related adverse events.
"Although tofogliflozin was effective regardless of baseline insulin level, it showed the highest efficacy in the H group," conclude the authors.
The authors disclosed financial ties to the pharmaceutical industry. Chugai Pharmaceutical Co. funded the original phase 3 trial.